Evommune (EVMN) Prepaid Assets (2024 - 2026)

Evommune's (EVMN) quarterly Prepaid Assets came in at $4.4 million in Q1 2026, up 2.64% on a QoQ basis from $4.3 million in Q4 2025.

Evommune (EVMN) Prepaid Assets (2024 - 2026) Analysis & Trends

Evommune (EVMN) has 3 years of Prepaid Assets data on file, last reported at $4.4 million in Q1 2026.

On a quarterly basis, Prepaid Assets changed N/A year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $4.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $4.3 million, up 119.61% from the prior year.
Prepaid Assets for Q1 2026 stood at $4.4 million, up from $4.3 million in the prior quarter.
Over the last five years, Prepaid Assets for EVMN reached as high as $5.9 million in Q3 2025 and fell as low as $1.9 million in Q4 2024.
Historically, Prepaid Assets has averaged $4.1 million across 3 years, with a median of $4.3 million in 2025.
On a YoY basis, Prepaid Assets climbed as much as 119.61% in 2025 and fell as far as 119.61% in 2025.
Year by year, Prepaid Assets stood at $1.9 million in 2024, then jumped by 119.61% to $4.3 million in 2025, then increased by 2.64% to $4.4 million in 2026.
Per Business Quant data, the three most recent Prepaid Assets figures were $4.4 million in Q1 2026, $4.3 million in Q4 2025, and $5.9 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Evommune	381.48 Mn	170.02 Mn	-

Download Data